- Home
- HSPO vs CRBP Comparison
HSPO vs CRBP Comparison
Compare HSPO & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- CRBP
- Stock Information
- Founded
- HSPO 2014
- CRBP 2009
- Country
- HSPO United States
- CRBP United States
- Employees
- HSPO N/A
- CRBP N/A
- Industry
- HSPO Blank Checks
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- CRBP Health Care
- Exchange
- HSPO Nasdaq
- CRBP Nasdaq
- Market Cap
- HSPO 92.0M
- CRBP 103.6M
- IPO Year
- HSPO 2022
- CRBP N/A
- Fundamental
- Price
- HSPO $11.65
- CRBP $8.18
- Analyst Decision
- HSPO
- CRBP Strong Buy
- Analyst Count
- HSPO 0
- CRBP 8
- Target Price
- HSPO N/A
- CRBP $61.38
- AVG Volume (30 Days)
- HSPO 3.5K
- CRBP 296.4K
- Earning Date
- HSPO 01-01-0001
- CRBP 03-11-2025
- Dividend Yield
- HSPO N/A
- CRBP N/A
- EPS Growth
- HSPO 2.63
- CRBP N/A
- EPS
- HSPO 0.28
- CRBP N/A
- Revenue
- HSPO N/A
- CRBP N/A
- Revenue This Year
- HSPO N/A
- CRBP N/A
- Revenue Next Year
- HSPO N/A
- CRBP N/A
- P/E Ratio
- HSPO $41.35
- CRBP N/A
- Revenue Growth
- HSPO N/A
- CRBP N/A
- 52 Week Low
- HSPO $10.80
- CRBP $7.64
- 52 Week High
- HSPO $12.41
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- HSPO 48.83
- CRBP 35.10
- Support Level
- HSPO $11.70
- CRBP $7.64
- Resistance Level
- HSPO $11.78
- CRBP $9.51
- Average True Range (ATR)
- HSPO 0.07
- CRBP 0.84
- MACD
- HSPO -0.02
- CRBP -0.05
- Stochastic Oscillator
- HSPO 0.00
- CRBP 13.71
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.